一个基于元学习的集合模型,用于解释性阿尔茨海默病诊断
Fatima Hasan Al-Bakri1, Wan Mohd Yaakob Wan Bejuri1,2, Mohamed Nasser Al-Andoli3
1Faculty of Information and Communication Technology, Universiti Teknikal Malaysia Melaka, Melaka 76100, Malaysia.
Diagnostics (Basel, Switzerland)
|July 12, 2025
概括
这项研究引入了一种可解释的AI框架,用于使用中切片MRI诊断阿尔茨海默病,实现高精度和提高临床采用透明度.
科学领域:
- 医疗成像医学成像
- 人工智能的人工智能
- 神经科学是一个神经科学.
背景情况:
- 对阿尔茨海默病 (AD) 诊断的可解释AI (XAI) 模型缺乏透明度,限制了临床使用.
- 当前XAI模型中的全尺寸MRI引入了过度的特征,造成了"黑子"问题.
研究的目的:
- 为阿尔茨海默病开发一种可解释的集体诊断框架.
- 提高AI模型在AD诊断中的透明度和临床相关性.
主要方法:
- 一个整体模型整合了随机森林,SVM,XGBoost和梯度提升,在临床数据和中切片轴性MRI上进行了训练.
- 该框架仅使用中切片MRI,专注于侧腔室以提高可解释性.
- 在最终的诊断决定中使用了元逻辑回归.
主要成果:
- 实现了高诊断准确度:99%在OASIS上和97.61%在ADNI上具有临床数据;99.38%在OASIS上和98.62%在ADNI上具有中切片MRI.
- 综合模式方法的准确性达到了99%.
- 人工智能始终将预测与横向心室扩张联系在一起,这是阿德的可验证临床生物标志物.
结论:
- 拟议的框架为阿尔茨海默病的透明AI驱动诊断提供了一步.
- 这项研究弥合了XAI对AD的诊断准确性和可解释性之间的差距.
- 使用中切片MRI增强了模型透明度和临床相关性.
关键词:
阿尔茨海默病的诊断阿尔茨海默病的诊断这是一个MMSE.临床数据 临床数据组合学习组合学习可解释的人工智能 (XAI)可解释的模型可以解释模型.侧心室的侧心室.这是一个元模型.中部切片MRI的MRI.神经成像是一种神经成像.更多相关视频
12:18A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.6K
05:47Evidence-based Knowledge Synthesis and Hypothesis Validation: Navigating Biomedical Knowledge Bases via Explainable AI and Agentic Systems
Published on: June 13, 2025
587
相关概念视频
01:26Alzheimer's Disease: Overview
673
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
673
01:22Alzheimer's Disease: Treatment
263
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
263